Journals / Üroonkoloji Bülteni / 2017 / Cilt: 16 - Sayı: 1

The Effect of Tumor Size on Oncologic Outcomes in Pathological T2 Stage Renal Cell Carcinoma Patients

Patolojik T2 Evreli Renal Hücreli Karsinom Olgularında Tümör Boyutunun Onkolojik Sonuçlar Üzerine Etkisi

Pages
1–3
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After median 36 (16- 176) months follow up time, local recurrence, distant metastasis, disease specific survival and overall survival rates of the patients were 19.4%, 7.6%, 82.6% and 77.6%, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the oncologic outcomes in T2 stage renal cell carcinoma (RCC) patients who underwent open radical nephrectomy and the effect of patient’s tumor size on the oncologic outcomes.
📊
Key Findings & Data:Materials and Methods: Data of patients who underwent open radical nephrectomy due to pre-diagnostic RCC between January 2010 and January 2014 and had the tumor size >7 cm were retrospectively evaluated.
💡
Conclusion & Impact:After median 36 (16- 176) months follow up time, local recurrence, distant metastasis, disease specific survival and overall survival rates of the patients were 19.4%, 7.6%, 82.6% and 77.6%, respectively.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate the oncologic outcomes in T2 stage renal cell carcinoma (RCC) patients who underwent open radical nephrectomy and the effect of patient’s tumor size on the oncologic outcomes. Materials and Methods: Data of patients who underwent open radical nephrectomy due to pre-diagnostic RCC between January 2010 and January 2014 and had the tumor size >7 cm were retrospectively evaluated. Two hundred thirty six patients with final pathologic diagnosis of RCC were included in the study. Patients were divided into two groups according to their tumor sizes (≤10 cm and >10 cm). The data of demographics, histological tumor subtype, tumor grade, survival after nephrectomy, local recurrence and metastasis were recorded. Results: Mean age and mean tumor size of patients at diagnosis were 58±11.5 years (28-80) and 10.4±2.6 cm (7.1-20), respectively. Out of 236 patients included in the study tumor size were ≤10 cm (group 1) in 120 patients and >10 cm (group 2) in 116 patients. After median 36 (16- 176) months follow up time, local recurrence, distant metastasis, disease specific survival and overall survival rates of the patients were 19.4%, 7.6%, 82.6% and 77.6%, respectively. When the two groups were compared; patients in group 1 were determined to have significantly higher disease specific survival (89% vs. 75%, p=0.007), higher overall survival rate (86% vs. 81%, p=0.001), lower local recurrence rate (13% vs. 25%, p=0.023) and lower local distant metastasis rates (5% vs. 12%, p=0.01). Conclusion: In patients whose tumor sizes are larger than 10 cm, lower disease specific survival and overall survival, higher local recurrence and distant metastasis rates were observed. Therefore, those patients should be followed more carefully after nephrectomy

Özet

Amaç: T2 evreli renal hücreli karsinom (RHK) olgularında açık radikal nefrektomi yapılan hastalarda onkolojik sonuçları ve bu hastalarda tümör boyutunun onkolojik sonuçlar üzerine etkisinin değerlendirilmesi. Gereç ve Yöntem: Ocak 2000 ile Ocak 2014 tarihleri arasında RHK ön tanısı ile açık radikal nefrektomi yapılan ve tümör boyutu >7 cm olan olguların verileri retrospektif olarak değerlendirildi. Nihai patoloji sonucu RHK olan 236 olgu çalışmaya dahil edildi. Olgular tümör boyutuna göre ( 10 cm) 2 gruba ayrıldı. Olguların demografik özellikleri, histolojik tümör alt tipi, tümör derecesi, nefrektomi sonrası sağkalım, lokal nüks ve metastaz verileri kaydedildi. Bulgular: Hastaların tanı anında ortalama yaşı ve ortalama tümör boyutu sırasıyla 58±11,5 (28-80) ve 10,4±2,6 cm (7,1-20) idi. Çalışmaya alınan 236 olgunun 120 tanesinde tümör boyutu 10 cm (grup 2) idi. Ortanca 36 (16-176) ay takip süresi sonunda hastalarda lokal rekürens oranı, uzak metastaz oranı, hastalığa özgü sağkalım oranı ve genel sağkalım oranı sırasıyla %19,4, %7,6, %82,6 ve %77,6 idi. Her iki grup karşılaştırıldığında; grup 1'deki hastaların istatistiksel olarak anlamlı derecede daha yüksek hastalığa özgü sağkalım oranı (%89'a %75, p=0,007) daha yüksek genel sağkalım oranı (%86'ya %81, p=0,001), daha düşük lokal nüks oranı (%13'e %25, p=0,023) ve daha düşük lokal metastaz oranlarına (%5'e %12, p=0,01) sahip olduğu belirlendi. Sonuç: Tümör boyutu 10 cm'den büyük olan olgularda hastalığa özgü sağkalım ve genel sağkalım oranının daha düşük olduğu, lokal rekürens ve uzak metastaz oranlarının daha yüksek olduğu izlendi. Bu nedenle bu hastalar nefrektomi sonrası dönemde daha dikkatli takip edilmelidir.

🔖

Cite This Article

HAMİDİ, N., SÜER, E., GÖKCE, M. İ., BEDÜK, M. Y., BALTACI, S. (2017). The Effect of Tumor Size on Oncologic Outcomes in Pathological T2 Stage Renal Cell Carcinoma Patients. Üroonkoloji Bülteni, Cilt: 16 - Sayı: 1, 1–3. https://ajindex.com/articles/334337

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Rendon RA, Kapoor A, Breau R, et al. Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J 2014;8:398-412
  2. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176:2353-2358
  3. Klatte T, Patard JJ, de Martino M, et al. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol 2008;179:1719-1726
  4. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-924
  5. Keegan KA, Schupp CW, Chaime K, et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012;188:391-397
  6. Sobin LH. TNM classification of malignant tumors. In: Sobin LH, Hermanek P, editör. UICC International Union Against Cancer. 1th ed. Springer: Berlin, Germany; 1987. p. 256-278
  7. Sobin LH. TNM classification of malignant tumors. In: Sobin LH, Gospodariwicz M, Wittekind C, editors. UICC International Union Against Cancer. 7th ed. Wiley-Blackwell, Malden: USA; 2009. p. 235-255
  8. Klatte T, Patard JJ, Goel RH, et al. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol 2007;178:35-40
  9. Waalkes S, Becker F, Schrader AJ, et al. Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol 2011;59:258-263
  10. Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 2010;58:588-595
  11. Bianchi M, Becker A, Trinh QD, et al. An analysis of patients with T2 renal cell carcinoma(RCC) according to tumour size: a populationbased analysis. BJU Int 2013;111:1184-1190
  12. Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999;162:1930-1933
  13. Yoo C, Song C, Hong JH, et al. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. J Urol 2008;180:486-491.